Status
Conditions
Treatments
About
The objective of this study is to evaluate the clinical tolerability of the NUVANCE™ Facial Rejuvenation System for correcting neck, mid-face and/or jowl ptosis.
Full description
This is a multicenter, prospective, single-arm study. The primary tolerability endpoint will be evaluated up to 30-days post-operatively. Secondary endpoints will be evaluated at 6-months. Extended follow-up will be conducted at 12-months, 24-months, and 36-months.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Subject who previously received surgical facial cosmetic treatment (procedure involving an incision):
Subject who previously received a cosmetic procedure with a dermal filler device and/or neurotoxin complex injectable within the last 9 months.
Subjects with a permanent facial implant.
Subjects planning on a cosmetic procedure with a permanent implant within 6-months of procedure.
Subjects planning on a cosmetic procedure with a dermal filler device and/or neurotoxin complex injectable within 6-months of procedure.
Subjects with significant ptosis where skin excision would be necessary.
Subject has an active infection (e.g. acne, herpes zoster) or inflammation (e.g. psoriasis, pemphigus vulgaris, cutaneous lupus erythematosus) affecting facial skin.
Subject has a history of a disorder that can affect wound healing (e.g. subjects pre-disposed to infection or history of keloid formation).
Subject with pre-existing facial abnormalities (e.g. deformities, Bell's palsy, scarring)
Subject with a significant psychiatric disorder judged by the clinical investigator that will interfere with the procedure
Any pre-operative findings that the surgeon identifies that makes the subject not a candidate for a minimally invasive facial cosmetic surgical procedure.
Primary purpose
Allocation
Interventional model
Masking
100 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal